Structure Therapeutics Overview
Structure Therapeutics (GPCR) has a ROE of -15.86%, below the sector sector average of -5.71%.
Get informed when a big investor buys or sells
+ Follow-15.86%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for GPCR is -15.86%. That is below the sector sector average of -5.71%. Investors often review this figure alongside Structure Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, GPCR currently prints -15.86% for ROE, while the sector average sits near -5.71%. That is roughly 177.7% below the sector mean. Large gaps often invite a closer look at Structure Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Structure Therapeutics converts resources into returns. At -15.86%, GPCR may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GPCR's ROE (-15.86%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
